BiotechTube

ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mycobacterium Infections, Nontuberculous

Conditions

Mycobacterium Infections, Nontuberculous

Trial Timeline

Apr 1, 2021 → Jan 15, 2026

NCT ID
NCT04677569

About ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS)

ALIS + Azithromycin + Ethambutol + ELC (matching placebo for ALIS) is a phase 3 stage product being developed by Insmed for Mycobacterium Infections, Nontuberculous. The current trial status is completed. This product is registered under clinical trial identifier NCT04677569. Target conditions include Mycobacterium Infections, Nontuberculous.

What happened to similar drugs?

3 of 7 similar drugs in Mycobacterium Infections, Nontuberculous were approved

Approved (3) Terminated (1) Active (3)
✅clarithromycin, rifabutinPfizerApproved
✅AzithromycinPfizerApproved
✅Azithromycin + Rifabutin/rifampinPfizerApproved
🔄Ethambutol hydrochloride + Clarithromycin + AzithromycinPfizerPhase 3
🔄ALIS + Azithromycin + Ethambutol + ELCInsmedPhase 3
🔄LAI (Liposomal Amikacin for Inhalation) 590 mgInsmedPhase 3
❌RHB-204 + PlaceboRedHill BiopharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04677569Phase 3Completed

Competing Products

20 competing products in Mycobacterium Infections, Nontuberculous

See all competitors
ProductCompanyStageHype Score
TrifluridineAmgenPre-clinical
26
clarithromycin, rifabutinPfizerApproved
43
AzithromycinPfizerPre-clinical
26
Ethambutol hydrochloride + Clarithromycin + AzithromycinPfizerPhase 3
40
AzithromycinPfizerPre-clinical
26
AzithromycinPfizerPre-clinical
26
AzithromycinPfizerPre-clinical
26
AzithromycinPfizerApproved
43
TigecyclinePfizerPhase 2
35
Azithromycin + Rifabutin/rifampinPfizerApproved
43
ALIS + Azithromycin + Ethambutol + ELCInsmedPhase 3
37
LAI plus multi-drug regimenInsmedPhase 2
32
Liposomal amikacin for inhalation (LAI) + placeboInsmedPhase 2
32
LAI (Liposomal Amikacin for Inhalation) 590 mgInsmedPhase 3
37
Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) + Ceftriaxone for Injection + Amoxicillin + Azithromcyin + clarithromycin + Clofazimine + Ethambutol + Amikacin Injection + tigecycline + Imipenem + Cilastatin + Cefoxitin + Amikacin (Inhalation) + linezolid + Trimethoprim / Sulfamethoxazole + Doxycycline + moxifloxacin + bedaquiline + RifabutinInnovivaPhase 2
36
Molgramostim nebulizer solutionSavaraPhase 2
21
Inhaled molgramostim + Antimycobacterial regimenSavaraPhase 2
29
Epetraborole + Epetraborole + Placebo + PlaceboAN2 TherapeuticsPhase 2
32
SPR720 + Placebo + Open-label Standard of CareSpero TherapeuticsPhase 2
17
RHB-204 + PlaceboRedHill BiopharmaPhase 3
22